The Ozempic Phenomenon: Unveiling the Truth Behind GLP-1 Medications
You’ve likely heard of Ozempic—it’s practically a household name by now. But did you know that the term “Ozempic face” was nearly crowned Word of the Year in 2025? (https://nypost.com/2025/04/25/health/people-with-ozempic-face-are-doing-this-to-fight-wrinkles-and-sagging/) (https://www.macquariedictionary.com.au/macquarie-dictionary-word-of-the-year-for-2025/) Yes, the cultural impact of this drug is undeniable. But here’s where it gets controversial: while Ozempic (https://track.revoffers.com/affc?offerid=359&affid=7888&urlid=11815) is a superstar in the GLP-1 medication world, it’s far from the only player. Drugs like Zepbound (https://track.revoffers.com/affc?offerid=359&affid=7888&urlid=11817), Mounjaro, Trulicity, and Victoza are also changing the game for people with obesity or Type 2 diabetes. But which one is right for you?
GLP-1 medications work by mimicking a natural hormone that helps you feel fuller longer, reduces appetite, and regulates blood sugar. They stimulate insulin production when blood sugar is high, prevent the liver from releasing excess sugar, and slow stomach emptying to avoid post-meal sugar spikes. Sounds like a win-win, right? And this is the part most people miss: with so many options available—shots, pills, daily doses, weekly doses—choosing the right one can feel overwhelming. Let’s break it down.
Semaglutide: The Household Name
Novo Nordisk’s Ozempic is arguably the most recognizable GLP-1 medication. Approved by the FDA in 2017 for Type 2 diabetes, it’s a once-weekly injection. Its sibling, Wegovy (https://track.revoffers.com/affc?offerid=359&affid=7888&urlid=11816), got the green light for obesity treatment in 2021 and uses a higher dose of semaglutide. But here’s the kicker: in 2025, the FDA approved a once-daily pill version of Wegovy (https://nypost.com/2025/12/23/health/fda-approves-new-daily-wegovy-pill-when-its-available/), making it even more convenient. Rybelsus, another semaglutide pill approved in 2019, was the first oral GLP-1 medication for Type 2 diabetes. However, there’s still no FDA-approved generic version of semaglutide, which could keep costs high.
Side Effects to Watch For: Nausea, vomiting, diarrhea, constipation, bloating, gas, and stomach pain are common. And if you have a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), steer clear—these drugs may increase the risk of thyroid tumors.
Tirzepatide: The Dual-Action Powerhouse
Tirzepatide stands out because it mimics both GLP-1 and GIP hormones. GIP promotes fat storage and can be more effective in certain ways. Lilly’s Mounjaro was approved for Type 2 diabetes in 2022, while Zepbound got the nod for obesity in 2023. Both are once-weekly injections with identical dosing schedules. But here’s the catch: there’s no FDA-approved generic version yet, and side effects like nausea, diarrhea, vomiting, and abdominal pain are common. As with semaglutide, avoid it if you have a history of MTC or MEN 2.
Liraglutide: The Veteran Player
Novo Nordisk’s Victoza (approved in 2010) and Saxenda (approved in 2014) are both liraglutide-based medications. The main difference? Dosage. Saxenda has a higher maximum dose than Victoza. Good news: generic versions of both were approved in 2024 and 2025, respectively. But here’s the debate: while these drugs are effective, they carry a boxed warning for thyroid C-cell tumors, raising questions about long-term safety.
Dulaglutide, Exenatide, and Lixisenatide: The Lesser-Known Contenders
Eli Lilly’s Trulicity (dulaglutide) is a weekly injection approved for Type 2 diabetes but not weight loss. It also carries a boxed warning for potential thyroid tumors in rats. Exenatide, the first GLP-1 approved in 2005, comes in various forms (Byetta, Bydureon, Bydureon BCise), though some have been discontinued in the U.S. Lixisenatide (Adlyxin) was approved in 2016 but discontinued in the U.S. in 2023, though it’s still available in Europe under the name Lyxumia.
What’s Next? The Future of GLP-1 Medications
Looking ahead to 2026, Lilly’s orforglipron (https://nypost.com/2025/11/28/health/next-level-ozempic-is-coming-inside-the-new-era-of-weight-loss-drugs/) is generating buzz. Unlike other GLP-1 drugs, it’s a small molecule that survives stomach acid, making it a once-daily pill. Expected to launch in mid-to-late 2026, it could be a game-changer for obesity treatment. Then there’s retatrutide (https://nypost.com/2025/01/06/health/ozempic-3-0-this-drug-causes-greatest-weight-loss-by-far/), nicknamed “GLP-3” or “triple G,” which mimics GLP-1, GIP, and glucagon. Injected weekly, it’s expected to be submitted to the FDA in 2026.
But here’s the question: With so many options and potential risks, how do we balance the benefits of these medications with their side effects? And as these drugs become more mainstream, will we see more cases of “Ozempic face” or other unexpected consequences? Let’s keep the conversation going—what are your thoughts on the future of GLP-1 medications? Share your opinions in the comments below!
Disclaimer: New York Post may receive revenue from affiliate and advertising partnerships for sharing this content and/or when you make a purchase.
